Takayasu's arteritis natural history, complications and prognosis: Difference between revisions
No edit summary |
|||
| Line 2: | Line 2: | ||
{{Takayasu's arteritis}} | {{Takayasu's arteritis}} | ||
{{CMG}} {{AE}} {{FKH}} | {{CMG}} {{AE}} {{FKH}} | ||
==Overview== | ==Overview== | ||
| Line 11: | Line 9: | ||
===Natural History=== | ===Natural History=== | ||
* The symptoms of Takayasu's arteritis typically develop between 15 and 30 years of age.<ref name="pmid19026150" /> | * The symptoms of Takayasu's arteritis typically develop between 15 and 30 years of age.<ref name="pmid19026150" /> | ||
* If left untreated, patients with Takayasu's arteritis may progress to develop [[high blood pressure]], [[stroke]] or [[heart failure]]. | * If left untreated, patients with Takayasu's arteritis may progress to develop [[high blood pressure]], [[stroke]], or [[heart failure]]. | ||
===Complications=== | ===Complications=== | ||
| Line 17: | Line 15: | ||
*Hardening and narrowing of [[blood vessels]] | *Hardening and narrowing of [[blood vessels]] | ||
*[[High blood pressure]] | *[[High blood pressure]] | ||
* | *[[Carditis]] | ||
*[[Heart failure]] | *[[Heart failure]] | ||
*[[Stroke]] | *[[Stroke]] | ||
| Line 25: | Line 23: | ||
===Prognosis=== | ===Prognosis=== | ||
* Takayasu arteritis is a chronic relapsing and remitting | * Takayasu arteritis is a chronic relapsing and remitting disease.<ref name="pmid16195161">{{cite journal |vauthors=Park MC, Lee SW, Park YB, Chung NS, Lee SK |title=Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification |journal=Scand. J. Rheumatol. |volume=34 |issue=4 |pages=284–92 |date=2005 |pmid=16195161 |doi=10.1080/03009740510026526 |url=}}</ref> | ||
* Takayasu arteritis is associated with significant [[morbidity]]. | * Takayasu arteritis is associated with significant [[morbidity]]. | ||
Revision as of 17:32, 1 May 2018
|
Takayasu's arteritis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Takayasu's arteritis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Takayasu's arteritis natural history, complications and prognosis |
|
FDA on Takayasu's arteritis natural history, complications and prognosis |
|
on Takayasu's arteritis natural history, complications and prognosis |
|
Takayasu's arteritis natural history, complications and prognosis in the news |
|
Blogs onTakayasu's arteritis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]
Overview
The symptoms of Takayasu's arteritis typically develop between 15 and 30 years of age. Common complications of Takayasu's arteritis include hardening and narrowing of blood vessels, High blood pressure, Heart failure, Stroke, Transient ischemic attack. The five year survival rate in Takayasu arteritis is over 90%.
Natural History
Natural History
- The symptoms of Takayasu's arteritis typically develop between 15 and 30 years of age.[1]
- If left untreated, patients with Takayasu's arteritis may progress to develop high blood pressure, stroke, or heart failure.
Complications
Common complications of Takayasu's arteritis include:[1]
- Hardening and narrowing of blood vessels
- High blood pressure
- Carditis
- Heart failure
- Stroke
- Transient ischemic attack (TIA)
- Aneurysm in the aorta
- Heart attack
Prognosis
- Takayasu arteritis is a chronic relapsing and remitting disease.[2]
- Takayasu arteritis is associated with significant morbidity.
- The five year survival rate in Takayasu arteritis is over 90%.
References
- ↑ 1.0 1.1 Phillip R, Luqmani R (2008). "Mortality in systemic vasculitis: a systematic review". Clin. Exp. Rheumatol. 26 (5 Suppl 51): S94–104. PMID 19026150.
- ↑ Park MC, Lee SW, Park YB, Chung NS, Lee SK (2005). "Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification". Scand. J. Rheumatol. 34 (4): 284–92. doi:10.1080/03009740510026526. PMID 16195161.